R-MTX-zanbrutinib in Secondary CNS Lymphoma

Clinical trial NCT05398224 · UNKNOWN

Trial details

NCT number: NCT05398224
Sponsor: Peking University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Secondary Central Nervous System Lymphoma

Start date: 2021-02-26
Primary completion: 2024-02-26
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.